XML 35 R21.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 28, 2018
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | Revenues by disaggregated category were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Product revenues: |  |  |  |  |  |  |
Gross product revenues | $ | 193,356 |  |  | $ | 111,148 |  |  | $ | 525,438 |  |  | $ | 289,365 |
Discounts and allowances | (30,410 | ) |  | (14,732 | ) |  | (82,384 | ) |  | (36,068 | )
Net product revenues | 162,946 |  |  | 96,416 |  |  | 443,054 |  |  | 253,297 |
Collaboration revenues: |  |  |  |  |  |  |
License revenues (1) | 51,323 |  |  | 54,335 |  |  | 152,261 |  |  | 74,706 |
Research and development service revenues (2) | 10,560 |  |  | 2,316 |  |  | 27,464 |  |  | 5,623 |
Other collaboration revenues (3) | 568 |  |  | (557 | ) |  | 2,445 |  |  | (1,221 | )
Total collaboration revenues | 62,451 |  |  | 56,094 |  |  | 182,170 |  |  | 79,108 |
Total revenues | $ | 225,397 |  |  | $ | 152,510 |  |  | $ | 625,224 |  |  | $ | 332,405 |
____________________
(1) | Upon the adoption of Topic 606, the allocation of proceeds from our collaboration partners, including upfront and milestone payments, between intellectual property licenses and research and development services as well as the resulting timing of recognition has changed. License revenues for the three and nine months ended September 30, 2018 included the immediate recognition of the portion of milestones that were allocated to the transfer of intellectual property licenses for those milestones for which it had become probable that a significant revenue reversal would not occur as well as royalty revenues from Ipsen and Genentech. License revenues for the three and nine months ended September 30, 2017 included the full recognition of substantive milestones achieved during the period, recognition of deferred revenues from upfront payments and a non-substantive milestone, which were being amortized over various periods, as well as royalty revenues from Ipsen and Genentech.
(2) | Research and development service revenues for the three and nine months ended September 30, 2018 included the recognition of deferred revenue for the portion of the upfront and milestone payments that have been allocated to the research and development service performance obligations which are being amortized through early 2030, as well as development cost reimbursements earned on our collaboration agreements. As described above, we did not allocate any of our upfront payments or milestones to research and development services prior to the adoption of Topic 606; therefore, Research and development service revenues for the three and nine months ended September 30, 2017 included only development cost reimbursements earned on our collaboration agreements.
(3) | Other collaboration revenues for the three and nine months ended September 30, 2018 included net losses on product supply services provided to Ipsen and Takeda and the profit on the U.S. commercialization of COTELLIC from Genentech. Other collaboration revenues for the three and nine months ended September 30, 2017 included only net losses on product supply services, since losses on the U.S. commercialization of COTELLIC for the period were instead included in Selling, general and administrative expenses.
Duri ng the three and nine months ended September 30, 2018, Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. License revenues and Research and development services revenues were recorded in accordance with Topic 606 during 2018 and Topic 605 in prior periods. Other collaboration revenues, which included the p rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were recorded in accordance with Topic 808 for all periods presented. Net product revenues disaggregated by product were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
CABOMETYX | $ | 158,262 |  |  | $ | 90,362 |  |  | $ | 428,317 |  |  | $ | 233,582 |
COMETRIQ | 4,684 |  |  | 6,054 |  |  | 14,737 |  |  | 19,715 |
Net product revenues | $ | 162,946 |  |  | $ | 96,416 |  |  | $ | 443,054 |  |  | $ | 253,297 |
Total revenues disaggregated by significant customer were as follows (dollars in thousands):
| Three Months Ended September 30,
| 2018 |  | 2017
| Dollars |  | Percent of total |  | Dollars |  | Percent of total
Ipsen | $ | 57,186 |  |  | 25 | % |  | $ | 50,680 |  |  | 33 | %
Caremark L.L.C. | 30,707 |  |  | 14 | % |  | 20,272 |  |  | 13 | %
Affiliates of McKesson Corporation | 26,597 |  |  | 12 | % |  | 14,575 |  |  | 10 | %
Diplomat Specialty Pharmacy | 17,946 |  |  | 8 | % |  | 20,460 |  |  | 13 | %
Accredo Health, Incorporated | 20,677 |  |  | 9 | % |  | 13,445 |  |  | 9 | %
Others, individually less than 10% of Total revenues for all periods presented | 72,284 |  |  | 32 | % |  | 33,078 |  |  | 22 | %
Total revenues | $ | 225,397 |  |  | 100 | % |  | $ | 152,510 |  |  | 100 | %
| Nine Months Ended September 30,
| 2018 |  | 2017
| Dollars |  | Percent of total |  | Dollars |  | Percent of total
Ipsen | $ | 145,038 |  |  | 23 | % |  | $ | 60,704 |  |  | 18 | %
Caremark L.L.C. | 83,516 |  |  | 13 | % |  | 52,526 |  |  | 16 | %
Affiliates of McKesson Corporation | 71,249 |  |  | 11 | % |  | 38,699 |  |  | 12 | %
Diplomat Specialty Pharmacy | 56,568 |  |  | 9 | % |  | 62,909 |  |  | 19 | %
Accredo Health, Incorporated | 58,677 |  |  | 9 | % |  | 36,504 |  |  | 11 | %
Others, individually less than 10% of Total revenues for all periods presented | 210,176 |  |  | 35 | % |  | 81,063 |  |  | 24 | %
Total revenues | $ | 625,224 |  |  | 100 | % |  | $ | 332,405 |  |  | 100 | %
Total revenues disaggregated by geographic region were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
U.S. | $ | 166,270 |  |  | $ | 97,807 |  |  | $ | 453,342 |  |  | $ | 260,853 |
Europe | 57,186 |  |  | 50,680 |  |  | 145,038 |  |  | 60,704 |
Rest of the world | 1,941 |  |  | 4,023 |  |  | 26,844 |  |  | 10,848 |
Total revenues | $ | 225,397 |  |  | $ | 152,510 |  |  | $ | 625,224 |  |  | $ | 332,405 |
Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
| Chargebacks and Discounts for Prompt Payment |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  | Total
Balance at December 31, 2017 | $ | 1,928 |  |  | $ | 1,795 |  |  | $ | 5,770 |  |  | $ | 9,493 |
Provision related to sales made in: |  |  |  |  |  |  |
Current period | 52,296 |  |  | 9,208 |  |  | 21,192 |  |  | 82,696 |
Prior periods | (520 | ) |  | 156 |  |  | 50 |  |  | (314 | )
Payments and customer credits issued | (50,726 | ) |  | (9,412 | ) |  | (17,070 | ) |  | (77,208 | )
Balance at September 30, 2018 | $ | 2,978 |  |  | $ | 1,747 |  |  | $ | 9,942 |  |  | $ | 14,667 |
Contract Assets and Liabilities under Topic 606 | Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):
| Contract Assets: Unbilled Collaboration Revenue |  | Contract Liabilities: Deferred Revenue
| Current Portion |  | Long-term Portion |  | Current Portion |  | Long-term Portion
Balance at December 31, 2017 | $ | — |  |  | $ | — |  |  | $ | 31,984 |  |  | $ | 238,520 |
Adoption of Topic 606 | 9,588 |  |  | 12,247 |  |  | (23,591 | ) |  | (213,079 | )
Balance at January 1, 2018 | 9,588 |  |  | 12,247 |  |  | 8,393 |  |  | 25,441 |
Increases as a result of a change in transaction price and recognition of revenues as services are performed | 37,744 |  |  | 4,037 |  |  | — |  |  | — |
Transfer to receivables from contract assets recognized at the beginning of the period | (9,109 | ) |  | — |  |  | — |  |  | — |
Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue | — |  |  | — |  |  | 873 |  |  | 3,712 |
Revenue recognized that was included in the contract liability balance at the beginning of the period | — |  |  | — |  |  | (6,114 | ) |  | — |
Other adjustments (1) | (13,734 | ) |  | (16,284 | ) |  | (3,152 | ) |  | (26,885 | )
Balance at September 30, 2018 | $ | 24,489 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,268 |
____________________
(1) | Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration